Evelo Biosciences Provides Clinical Updates – Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles (EVs) –– First EV...

Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally...

Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial – Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been...